Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern

Table 3

Eculizumab doses administered to patient 3 and analytical data after the corresponding eculizumab administration.

Phase	Week: dose number	ECU; IV (mg)	Platelets; (number/μL)	LDH; (IU/L)	Hemoglobin (mg/dL)	Haptoglobin; (mg/dL)	Schistocytes per field	Serum creatinine; (mg/dL)
Initiation	1: 1	900	93,000	728	8.3	Below the limit	5–8	4.3
	2: 2	900	30,000	1,170	10.5	Below the limit	8	5.6
	3: 3	900	81,000	1,957	9	—	—
	4: 4	900	71,000	1,230	7.8	Below the limit	7–10	0.9
Maintenance	5:	1,500	64,000	1,675	10.5	Below the limit	—	2.3
	7: 6	1,500	135,000	1,483	7.9	—	0	2.5
	9: 7	1,200	297,000	794	8.2	249	0	4.3
	11: 8	1,200	198,000	811	9	99	0	5.3
	13: 9	1,200	269,000	560	9.2	—	—	5.2

The modified eculizumab dosage pattern is highlighted in bold: the 5th and 6th doses of eculizumab were increased from 1,200 mg to 1,500 mg.
of rituximab. patient was admitted into the ICU due to acute lung edema at the third week of treatment with eculizumab. There she was intubated and started on continuous venovenous hemofiltration and empiric wide-spectrum antibiotherapy. The patient showed good evolution and was discharged from the ICU one week later.
ECU: Eculizumab; LDH: Lactate dehydrogenase; ICU: Intensive care unit.